Totally Healthy Pets - A Friend in Need is a Friend In Deed

Welcome, My name is Dr. Scooter

I’ve been commissioned by New England Institute for infection &

Immunity to Introduce Immu-Treats. I’ve assembled a number of my

distinguished colleagues to help you understand the significance of

this development. I have worked very closely with NEInstitute on this

project and am convinced of its remarkable impact on the health and

well-being of my family and friends.

Immu-Treats® are the result for several years of research and development by the scientists at the

New England Institute for Infection and Immunity. The goal of this research was to produce a multi-

faceted treat for mammals and especially for dogs. This development utilizes the same immune

boosting ingredient that is in our human version called Glucanol®. The active ingredient in

Glucanol® is cuurently involved in 8 FDA approved clinical trials to treat severe infections and

many forms of cancer.

http://www.clinicaltrials.gov/ct2/results?term=beta+glucan+and+cancer.

Immu-Treats® also contain Glucosamine and Chondroitin for healthy hips and joints and to also

help with cartilage growth and regeneration. A vitamin package has been added to Immu-Treats® to

insure the proper vitamin intake for healthy bodily functions and a shiny coat. Immu-Treats® are

supplied as medium sized bone containing real liver flavor, a Biscotti texture for cleaner teeth and

enhanced tartar control.

Manipulating the immune system for animal health benefits is not new. Vaccines have been used

for decades for preventative purposes. Research and development efforts are increasingly being

focused on immunotherapy drugs to treat disease by directly activating the immune response to a

specific target. In the last 20 years, there has been significant development in immunotherapy for

the treatment of cancer. The immune system consists of two major subsystems: innate immunity

and acquired (adaptive) immunity. As its name implies, innate immunity is the protection mammals

are born with. Innate immune cells are the body’s first line defenders. Innate immune cells attack

pathogens in a non-discriminatory manner. Adaptive immunity is learned. The adaptive immune

system recognizes molecules unique to a foreign pathogen and maintains a “memory” of these

pathogens so it can respond more quickly to a subsequent infection.

Most pharmaceutical development, however, has been focused on utilizing the adaptive arm of the

immune system (e.g. vaccines, antibodies, T-cells, B-cells). Recently, pharmaceutical companies

have placed greater focus on compounds that can activate the innate immune system (e.g. toll-like

receptors, growth factors, cytokines) to work in combination with the adaptive immune system for

a more complete immune response against disease

Immu-Treat’s® active ingredient is Glucanol®, a highly purified and patented pharmaceutical grade

molecule called 1,3-1,6 beta glucan. Glucanol’s® technology is focused on the innate immune

system. The significance of this technology is its ability to enhance the natural innate immune

function and in certain circumstances, engage and direct the innate immune cells in novel ways

against specific diseases. In these targeted applications, Glucanol® acts as a keystone, engaging

both the innate and adaptive immune systems to work in concert for a more complete immune

response

The immune system is our number one defense against infections and some diseases including

cancer. The presence of foreign or abnormal cells in the body triggers the release of highly

specialized cells in the blood and humeral tissues that target, trap and rid your pets body of these

invaders. However, there are circumstances in our pets life that compromises its immune system

causing it to function at a lower level. Diseases such as allergies, AIDS, cancer chemotherapy or

radiation and environmental chemicals including pesticides and dioxin are all conjointly top

offenders that degrade the immune system. Bacterial and viral infections are now known to be the

basis for stomach cancer, liver cancer, spleen tumors, cardiovascular disease and many other

diseases showing no prior correlation to infectious agents

The animal immune system is a network of cells and proteins that interact to protect against

foreign challenges. This complex system is subdivided into innate and adaptive immune systems.

The innate immune system is the first line of defense against pathogens and is characterized as

“non-specific” because it functions against pathogens in general. Adaptive immunity is initiated

following the activation of the innate system and is characterized as “specific,” because it

generates long lasting immunological memory to specific antigens within the foreign pathogens or

on their surface. There are hundreds of different types of receptors on the surface of immune cells

that control and activate the complex cellular and molecular interactions between these two

subsystems. In real-life, these two arms work in concert to protect the body from health challenges.

The innate immune system is composed of billions of white blood cells that are the body’s first line

of defense. These cells, which can distinguish between self and non-self, patrol the body in search

of foreign pathogens such as bacteria, viruses and cancer cells. Once such invaders are detected,

cells of the innate immune system respond rapidly (in minutes or hours) with a number of non-

specific killing mechanisms designed to destroy the intruding organisms or cells. Innate immune

cells also play an important role in initiating the adaptive immune response which is slower (in

days or weeks) yet generates a specific killing mechanism targeting a particular intruding

organism, such as a specific bacteria or virus or cancer cell.

Although the innate immune system is considered “non-specific,” it does recognize highly conserved,

pathogen-specific molecules known as Pathogen Associated Molecular Patterns (PAMPs). Innate immune

response is often initiated by the binding of PAMPs to select receptors on innate immune cells. Simply

put, PAMPs are natural molecular structures that the innate immune system uses to recognize foreign

pathogens and to trigger innate immune cells to kill the pathogen and to activate the adaptive immune

system.

This process of recognition is mediated through several receptors found on innate immune cells.

Functionally, the immune response can differ depending on what type of immune cell and which receptor

the PAMP is bound to and whether it is bound by an individual receptor or multiple receptors at the same

time. Receptor binding of PAMPs can trigger an immune response that includes engulfing or eating the

pathogen (phagocytosis), sending chemical messages called “cytokines” to other immune cells to

activate them, and killing the pathogen or cancer cell. Glucanol® activates this innate immune cell

function against other disease targets.

The technology used in Immu-Treats® involves natural PAMP structures found in the cell walls of yeast.

These compounds are chains of glucose molecules (polysaccharides or glucans) connected by a very

specific linkage pattern (beta 1,3/1,6 glucan). There has been significant research published on the ability

of PAMPs to induce immune responses. Immu-Treats utilize patented technology surrounding the

production, purification, and characterization of natural PAMP molecules that can be used as immune

modulators. The binding of these molecules to specific receptors on innate immune cells activates select

immune responses that can be used to target various diseases.

This technology includes a number of patented polysaccharide compounds that are well characterized as

to form, size and shape. The research supported by these patents has identified the specific mechanism

of action of these compounds. The significance of the technology is that these compounds each have

unique molecular features that result in their ability to bind to specialized innate immune cell receptors

that can trigger select immune responses. Research has demonstrated that when these compounds are

used in combination with certain drug therapies, they have a synergistic effect leading to significantly

enhanced efficacy. The result is a platform technology with the potential to be used in multiple

combination therapies against multiple disease indications